Engineers Gate Manager LP Myovant Sciences Ltd. Transaction History

Engineers Gate Manager LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$7.78 - $14.69 $106,928 - $201,899	13,744 New	13,744 $171,000
Q3 2021 Nov 15, 2021	SELL	$18.94 - $26.99 $383,913 - $547,087	-20,270 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$17.07 - $24.56 $144,378 - $207,728	8,458 Added 71.61%	20,270 $462,000
Q1 2021 May 17, 2021	BUY	$20.46 - $25.18 $241,673 - $297,426	11,812 New	11,812 $243,000
Q4 2020 Feb 16, 2021	SELL	$13.8 - $27.62 $598,740 - $1.2 Million	-43,387 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$14.05 - $22.6 $348,819 - $561,090	24,827 Added 133.77%	43,387 $610,000
Q2 2020 Aug 17, 2020	BUY	$7.34 - $20.84 $136,230 - $386,790	18,560 New	18,560 $383,000

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

Stay updated on Engineers Gate Manager LP with notifications on news.